Here, we report a MNT measuring neuraminidase activity as the read-out (NA-MNT) for quantitative analysis of neutralizing antibodies against avian influenza viruses. NA-MNT is a reliable and high throughput method which could facilitate the development of candidate pandemic influenza vaccine. == Introduction == Newly emerged avian influenza A viruses have a significantly negative impact on public health. Specifically, the highly pathogenic avian influenza H5N1 virus has infected 860 humans, with a mortality rate of 52%, according to the World Health Organization [1], whereas H7N9, first emerged in 2013, has infected over 1500 humans and caused 612 deaths TAK-438 (vonoprazan) [2]. Effective vaccines against these viruses in humans are urgently needed. As an important part of vaccine development, standard and reliable methods with high-throughput capacity are needed to evaluate the immune response elicited by influenza vaccines. Several candidate assays, including neutralization and hemagglutination TAK-438 (vonoprazan) inhibition (HI) assays, have been used to assess the efficacy of the influenza vaccines. The microneutralization test (MNT) has proven to be useful in evaluating the immunogenicity of pandemic influenza H5N1 or H7N9 vaccines [36], as well as determining the prevalence of H5N1 in human populations that have had contact with infected birds, given that it measures the neutralizing activities of TAK-438 (vonoprazan) antibodies with greater sensitivity than the traditional HI assays [3,4,7]. The MNTs have a similar neutralization step, in which sensitive cells are inoculated with a mixture of viruses and serum, but have different final steps as read out including microscopically observing cytopathic effects (CPEs), assessing virus hemagglutination with red blood cells, or detecting viral proteins by ELISA. Using the CPE method, some influenza viruses induce uncharacteristic CPEs, which makes view of the results subjective and dependent on the encounter of the observer. Although ELISA-MNT is definitely more sensitive than HI as it quantifies viral nucleoproteins by ELISA, it is a relatively long process with multiple methods, making it challenging for assay standardization. Indeed, considerable variations have been observed in inter-laboratory assessment studies TAK-438 (vonoprazan) [6,8]. In this study, we describe an MNT that actions neuraminidase (NA) activity as the readout (NA-MNT). Only lysates from cells infected with disease and NA substrates are needed. This simple method was used here to measure antibody titers induced by pandemic influenza vaccines in comparison with results generated by both HA assay and ELISA-MNT. == Materials and methods == Rabbit Polyclonal to TSN == Cells and viral strains == MDCK (Madin-Darby canine kidney) cells were cultured in Dulbeccos revised essential medium (DMEM) comprising 1% penicillin/streptomycin (Gibco Existence Technologies, Grand Island, NY, USA), 10% fetal calf serum (Hyclone South logan, UT, USA) and 1% L-glutamine and managed inside a 5% CO2 incubator at 37C. The viruses tested were vaccine strains from The National Institute for Biological Requirements and Control (NIBSC; Potters Barr, UK), including A/Vietnam/1194/2004 NIBRG-14 (H5N1) and A/Anhui/01/2013 NIBRG-268 (H7N9). All viruses were cultivated in 10-day-old embryonated chicken eggs for 4896 h at 35C. Cellular debris from harvested allantoic fluids was eliminated by centrifugation at 3000 rpm for 10 min, with the harvested viral aliquots becoming stored at 70C. The infectious titers of the viral stocks were identified as explained previously [9]. The 50% cells culture infective dose (TCID50) was determined using ReedMuench method. == NA assays == NA assays were performed as explained previously [10] using the substrate 2-O-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid (MU-NANA) (Sigma-Aldrich, St Louis, MO, USA). Cleavage of MU-NANA by NA releases fluorescent methylumbelliferone which is definitely consequently quantified using a fluorescence plate reader. == Human being serum samples == A panel of serum samples was collected from 40 volunteers who received two doses of inactivated H5N1 influenza vaccine (A/Vietnam/1194/2004 NIBRG-14, 15 g HA/dose), kindly provided by Wuhan Institute of Biological Products Co., Ltd, Wuhan, China. The trial was authorized by the Honest Committee of Jiangsu Provincial Center for Disease Control and Prevention and authorized atchinadrugtrials.gov.cn(ID: CTR20131644). Serum samples were also collected from human subjects vaccinated with H7N9 influenza vaccine (A/Anhui/01/ 2013 NIBRG-268, 30 g HA/dose), kindly.
Recent Posts
- Bisecting GlcNAc was also associated with a decrease in core fucose
- A scholarly research by researchers on the Mayo Medical clinic reported that, among sufferers who had been positive for CASPR2 and anti-LGI1 antibodies, about 25% had autonomic symptoms, which orthostatic hypotension and reduced perspiration were the most frequent symptoms (5)
- First, involvement was voluntary among a convenience test, which might have got affected representativeness a range bias cannot completely be excluded as a result, because of the fact that in Italy also, in the initial waves specifically, Lombardy and Piedmont were the epicenters from the epidemic
- Between your two patient groups, there is no difference with regards to age [median (interquartile range (IQR) 65 (59) for COVID19positiveversus66 (74) for COVID19 vaccinated, respectively,P=076], gender [men: 19/35 (543%) vs 16/35 (457%), respectively,P=047], body system mass index (median 27 vs 26kg/m2, respectively,P=056) asymptomatic disease [6/35 (182%) in both groups,P=1], prior lines of treatment [range: 17 vs 16, respectively,P=099], and kind of treatment (P=087)
- Furthermore, DNA-ZIKV/MVA-ZIKV also elicited a craze to higher degrees of neutralizing antibodies against ZIKV compared to the homologous immunization regimens
Recent Comments
Archives
- February 2026
- January 2026
- December 2025
- November 2025
- June 2025
- May 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
Categories
- Orexin Receptors
- Orexin, Non-Selective
- Orexin1 Receptors
- Orexin2 Receptors
- Organic Anion Transporting Polypeptide
- ORL1 Receptors
- Ornithine Decarboxylase
- Orphan 7-TM Receptors
- Orphan 7-Transmembrane Receptors
- Orphan G-Protein-Coupled Receptors
- Orphan GPCRs
- OT Receptors
- Other Acetylcholine
- Other Adenosine
- Other Apoptosis
- Other ATPases
- Other Calcium Channels
- Other Cannabinoids
- Other Channel Modulators
- Other Dehydrogenases
- Other Hydrolases
- Other Ion Pumps/Transporters
- Other Kinases
- Other MAPK
- Other Nitric Oxide
- Other Nuclear Receptors
- Other Oxygenases/Oxidases
- Other Peptide Receptors
- Other Pharmacology
- Other Product Types
- Other Proteases
- Other RTKs
- Other Synthases/Synthetases
- Other Tachykinin
- Other Transcription Factors
- Other Transferases
- Other Wnt Signaling
- OX1 Receptors
- OXE Receptors
- Oxidative Phosphorylation
- Oxoeicosanoid receptors
- Oxygenases/Oxidases
- Oxytocin Receptors
- P-Glycoprotein
- P-Selectin
- P-Type ATPase
- P-Type Calcium Channels
- p14ARF
- p160ROCK
- P2X Receptors
- P2Y Receptors
- p38 MAPK
- p53
- p56lck
- p60c-src
- p70 S6K
- p75
- p90 Ribosomal S6 Kinase
- PAC1 Receptors
- PACAP Receptors
- PAF Receptors
- PAO
- PAR Receptors
- Parathyroid Hormone Receptors
- PARP
- PC-PLC
- PDE
- PDGFR
- PDK1
- PDPK1
- Peptide Receptor, Other
- Peptide Receptors
- Peroxisome-Proliferating Receptors
- PGF
- PGI2
- Phosphatases
- Phosphodiesterases
- Phosphoinositide 3-Kinase
- Phosphoinositide-Specific Phospholipase C
- Phospholipase A
- Phospholipase C
- Phospholipases
- Phosphorylases
- Photolysis
- PI 3-Kinase
- PI 3-Kinase/Akt Signaling
- PI-PLC
- PI3K
- Pim Kinase
- Pim-1
- PIP2
- Pituitary Adenylate Cyclase Activating Peptide Receptors
- PKA
- PKB
- PKC
- PKD
- PKG
- PKM
- PKMTs
- PLA
- Plasmin
- Platelet Derived Growth Factor Receptors
- Platelet-Activating Factor (PAF) Receptors
- Uncategorized